NCT02043886

Acarbose, Postprandial Hypotension and Type 2 Diabetes

The Use of Acarbose to Treat Postprandial Hypotension in Older Adults With Type 2 Diabetes

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 15 (actual)
• Sponsor: University of British Columbia · Academic / Other
• Sex: All
• Age: 65 Years
• Healthy volunteers: Not accepted

Summary

Postprandial hypotension carries a risk of significant morbidity and morbidity including syncope, falls, dizziness, fatigue, stroke and myocardial infarction. Current therapy consists of dietary manipulation (smaller meals) caffeine and octreotide injections all of which are suboptimal and poorly studied. The study hypothesis is that administration of Acarbose will decrease the drop in blood pressure and increase in heart rate in response to food in people with Type 2 diabetes. Acarbose suppresses postprandial glycemia be slowing digestion in the small intestine and delaying gastric emptying. This is a placebo-controlled cross over study involving 2 - 4 hour Meal Tests. During the meal tests heart rate, blood pressure, cerebral artery velocity will be measured. During one meal test subjects will receive Acarbose 50 mg po and during the other will receive placebo. Order of treatment assignment will be done in randomized fashion. A total of approximately 200 cc of blood will be drawn during each meal test.

Conditions

• Type 2 Diabetes
• Postprandial Hypotension

Interventions

Type	Name	Description
DRUG	Acarbose	Acarbose 50 mg by mouth given during Meal Test
DRUG	Placebo	Non active substance matched to look like Acarbose 50 mg tablets. Taken by mouth during Meal Test.

Timeline

• Start date: 2007-06-01
• Primary completion: 2013-01-01
• Completion: 2014-05-01
• First posted: 2014-01-23
• Last updated: 2017-06-28

Locations

1 site across 1 country: Canada